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Long term treatment of polymyalgia rheumatica
with deflazacort
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Abstract
Objectives-To evaluate the long term
efficacy and tolerability of deflazacort, a
corticosteroid reputed to have only minor
side effects, in the treatment of poly-
myalgia rheumatica (PMR).
Methods-In a prospective open study,
deflazacort was administered at an
average initial dose of 21-8 mg/day for a
mean period of 19 months in 40 patients
with PMR.
Results-A highly significant improve-
ment of clinical and laboratory param-
eters occurred one month after therapy
onset. This improvement persisted for the
whole study period. Laboratory param-
eters of tolerability did not change during
the study. Mild to moderate steroid-
related side effects occurred in 57.9% of
the patients
Conclusions-Deflazacort is effective in
the treatment ofPMR. Its long term safety
profile may be superior to that of other
corticosteroids.
(Ann Rheum Dis 1994; 53: 331-333)
most common starting doses were 15 mg/day
(15 patients, 37 5%), 30 mg/day (14 patients,
35%), and 6 mg/day (four patients, 10%). The
highest dose (60 mg) was used in two patients
with concomitant giant cell arteritis. Patients
were evaluated monthly for one year and every
six months thereafter. Deflazacort was tapered
by about 20% if the patient was asymptomatic
and ESR was reduced. Side effects were
searched with a questionnaire and by physical
examination.
In PMR recurrences (defined as signs or
symptoms of PMR and/or giant cell arteritis
requiring higher doses of steroids), deflazacort
was increased to the latest level that had
kept the patient asymptomatic. A relapse
was defined as signs or symptoms of PMR
requiring corticosteroid therapy after its
discontinuation.
Statistics included one-way ANOVA,
Student's t test, chi-square test with Yates'
correction and the Kaplan-Meier method for
survival curves. All the tests were two-tailed.
The 'post-hoc comparison' was evaluated by
the least significant difference method.
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Polymyalgia rheumatica (PMR) is a disease of
the elderly that causes pain and stiffness of the
limb girdles, fever, weight loss, and an
elevation of non-specific indicators of inflam-
mation.' Corticosteroids are its treatment of
choice. They control the symptoms of most
patients and may prevent serious ocular
complications when giant cell arteritis is
associated. However, prolonged use of cortico-
steroids can result in multiple side effects.
The efficacy and tolerability of deflazacort,
a derivative of prednisone,2 was evaluated in
PMR. Deflazacort is generally associated with
milder bone damage than other cortico-
steroids3 and with minor effects on glucose
metabolism.4
Patients and methods
We studied 40 consecutive outpatients with
active PMR diagnosed according to Jones and
Hazleman.5 Only patients older than 50 years
with an erythrocyte sedimentation rate (ESR)
greater than 40 mm/hour were included.6 They
had not received steroids and gave their
informed consent.
Deflazacort was administered at a mean
starting dose of 21 8 mg/day with a range of
6-60 mg depending on severity of disease. The
Results
PATIENTS
The mean age of the 40 patients (24 women/
16 men) was 70 7 years (range 50-91 years).
Patients were referred 4-6 months after
the onset of PMR on average (range 1-14
months).
Twenty seven patients were allowed to
continue treatment with NSAIDs at low doses.
Of these, 15 received NSAIDs for less than
three months and 12 for 9 7 months in average.
The dose of NSAIDs in these 12 patients was
constant throughout the study.
FOLLOW UP
Two patients were lost to follow up on the first
and third month. In the remaining 38 patients,
the treatment lasted a mean of 18-9 months
(range 9-48 months). Of the 23 patients with
remission, seven required deflazacort for less
than one year, and 20 for less than two years
(fig 1). In these patients, the mean follow up
after discontinuation of deflazacort was 9 9
months (range 1-33 months). The mean daily
dose of deflazacort was 11-4 mg (range
2-5-32-2 mg) and the cumulative dose ranged
between 0 9 g and 27 g (mean 6-6 g).
Twenty three of 38 patients (60-5%) had no
exacerbations; 13 patients had one exacerbation,
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1 had two and 1 had four. Except for two cases
of frank temporal arteritis, exacerbations were
mild. All exacerbations could be controlled by
a temporary increase of deflazacort. No
relapses were seen in 21/23 (91-3%) patients.
Only two patients had relapse two months after
discontinuing deflazacort.
CLINICAL EFFICACY
The visual analogue scale of pain (F = 20-9,
p < 0-00001) and the duration of morning
stiffness (F = 42 3, p < 0 00001) decreased at
one month of follow up and on the subsequent
control visits (fig 2).
LABORATORY DATA ON TREATMENT EFFICACY
ESR was raised in all patients (mean 72-9 mm/
hour, range 40-114 mm/hour) on the baseline
values. After one month, the mean ESR value
was 30-6 mm/hour (t = 10-95, p < 0 00001). In
the following months, ESR further decreased
(F = 32-583 p < 0 00001) (fig 2). CRP (F = 8-4,
p < 0-00001) and alpha-2-globulins (F = 6'8,
p = 0.00001) also decreased; haemoglobin
increased (F = 5.3, p = 0-0002).
CLINICAL TOLERABILITY
No significant changes in mean blood pressure
took place during treatment. Hypertension
(25 mm/Hg over baseline values) was observed
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Figure 1 Kaplan-Meier survival curve showing the time
ofcessation of treatment because of onset of remission (used
as end point) in the study population.
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Figure 2 Changes (+SEM) in the mean duration of
morning stiffness (solid squares; solid line) and in mean
ESR (open squares; dashed line) during deflazacort
treatment ofpatients with polymyalgia rheumatica.
Differencesfrom baseline values ofmoming stiffness were
highly significant in month 2-24 (p < 0 00001) andfor
months 1 and 30-36 (p < 0 0001). Differencesfrom
baseline values ofESR were highly significant on months 1
through 18 (p < 0-00001) andfor months 30 and 36
(p < 0 001).
in five patients who were not taking NSAIDs;
in three, hypertension was present on the first
visit. It was controlled by antihypertensive
therapy.
The average body weight reported by the 40
patients before the onset of PMR was 68 kg
(range 43-5-114-5 kg). It was 66- 1 kg (t = 3-83,
p < 0.0004) at the first visit. During treatment,
weight increased (F= 1-43, p=0 1956) but
did not reach pre-disease levels.
LABORATORY DATA ON DRUG TOLERABILITY
The mean white blood cell count, the mean
lymphocyte count, as well as the mean serum
total protein concentration, transaminases,
urea, creatinine, sodium and potassium
remained unchanged throughout the study.
The mean platelet count (339 x 109/L at
baseline) decreased significantly during follow
up (F = 2-42, p = 0-04 1). However, all values
remained within normal range.
The mean serum fasting glucose was normal
throughout the study, despite a significant
decrease seen on the six month control visit
(5-28 v 4-97 mmol/L, t = 2-26, p = 0 032).
SIDE EFFECTS
Thirty six side effects occurred in 22/38
(57 9%) patients (table). These were present in
17/23 (739/9%) women and in 5/15 (33 3%)
men (chi-square = 4-58, p = 0-032).
There was no significant difference in age,
initial deflazacort dose, mean daily deflazacort
dose, concomitant use of NSAIDs, and
number of exacerbations or relapses between
patients with adverse effects and those without.
In the first group, treatment was longer [mean
(SD) 21-9 (11-4) v 14-7 (4 7) months, t = 2-39,
p = 0 022] and the mean (SD) cumulative dose
higher [7910 (5716) gm v 4708 (2226) gm,
t=2-12,p=0-041].
Discussion
The efficacy and tolerability of deflazacort has
not been tested on a long term basis in patients
with PMR. In a recent double-blind study
comparing deflazacort with prednisone in
Side effects ofdeflazacort treatment in patients with
polymyalgia rheumatica
Side effect Number of Mean interval* Mean
patients (months) cumulative
dose (mg)
Weight gain 7 8-6 4479
Cystitis 7 12 9 5532
Hypertension 5 10 6 6248
Dyspepsia 4 3 0 1445
Tachycardia 3 15 3 7050
Fracture 2 5 0 3982
Diarrhoea 2 6-5 2126
Exacerbation
of cataract 2 17 5 4342
Exacerbation
of diabetes 1 15 0 14850
Nausea 1 1 0 90
Vertigo 1 8-0 4815
Herpes zoster 1 33 0 9540
Of the 22 patients who experienced a side effect, 11 had one
side effect and the other 11 had two or more side effects. *Time
between beginning of treatment and the occurrence of a given
side effect.
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chronic inflammatory disorders, two patients
with PMR have been treated with deflazacort
for three months with a good response.2 In
another short term trial,7 Lund et al tested
patients with PMR for the relative anti-
inflammatory potency of deflazacort versus
prednisone. These authors concluded that the
potency of deflazacort expressed on a weight
for weight basis was less than that of
prednisone. The median dose of 15 mg of
deflazacort we used is equivalent to a value of
8-3 mg to 12-5 mg of prednisone on an
equimolar basis.7 This relatively low dose of
deflazacort reduced both symptoms and
objective parameters of disease activity in
PMR.
We found a recurrence rate of polymyalgic
symptoms of 39 5%. It is lower than the
reported values of 560/oS and 108-5%9 with
other steroids but similar to the 37/5% value
of Kyle and Hazleman.'I Accordingly, also the
relapse rate of 8/3% is lower than the reported
values of 35.8%,/, 35 10%,8 and 25 7%.' Under
reporting of late relapses may have occurred in
our study because the follow up after
deflazacort withdrawal was only 9-9 months on
average. However, one year after completion of
the study, none of the patients returned to the
clinic because of a relapse.
In our patients, median treatment was 20
months. With different corticosteroids it was
37.3 months8 and 25-7 months.'2 These
observations suggest that deflazacort has an
anti-inflammatory effect that is at least
comparable to that of prednisone.
The number of patients who experienced at
least one side effect was 22/38 (57-9%),
compared with a reported prevalence of
68 1%/I9 or another of 8 1%1O with prednisolone.
The latter study is the only prospective study
on side effects of steroids in PMR. Two other
studies report side effect prevalences of 7.5%12
and 22 6%./ Their retrospective design,
however, may have biased interpretation of
results because data were obtained from
patients' records.
In all patients, body weight increased
significantly after six and 12 months of
treatment. However, if weight loss is con-
sidered a constitutional sign associated with
untreated PMR, the mean weight did not
exceed the pre-disease values reported by the
patients.
The prevalence of bone fractures was lower
(5.2%) than that of 13.5% observed in the
UK,'3 but comparable to those of 5.8%l and
4%8 in the USA. Vertebral fractures occurred
after five months of treatment in two patients.
Both patients reported bone fractures even
before treatment with deflazacort.
Of the two patients with type II diabetes
mellitus, one showed progression of the disease
during treatment (fasting blood glucose
previously normal on diet alone that increased
to 8'6 mmolL). Diabetes was controlled by
oral hypoglycaemic agents. New cases of
diabetes mellitus were not observed during the
study. Mean fasting blood glucose in the
remaining patients decreased slightly on the six
month control. This observation may be due to
the patients' paying more attention to their diet
after being informed about the risks of
corticosteroid therapy.
In conclusion, deflazacort has anti-
inflammatory effects that are at least equivalent
to those of prednisone in patients with PMR.
Although no long term comparison with
prednisone was performed, we propose that
deflazacort is better tolerated. These con-
siderations indicate the need for a controlled
comparative trial. PMR constitutes a good
model for this type of comparison because this
disease has a typical, prompt response to
corticosteroids and requires long term but
usually definite treatment.
Dr Carlo M Pesce, Istituto di Anatomia Patologica, Universita
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